Monoclonal Antibody Therapeutics Market Report 2026

Monoclonal Antibody Therapeutics Market Overview

• Monoclonal Antibody Therapeutics market size has reached to $224.62 billion in 2025 • Expected to grow to $396.1 billion in 2030 at a compound annual growth rate (CAGR) of 11.9% • Growth Driver: Rising Prevalence Of Autoimmune Diseases Fueling The Growth Of The Market Due To Increasing Demand For Targeted Immunotherapy • Market Trend: Companies Introducing Bispecific Monoclonal Antibodies To Enhance Treatment Efficacy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Monoclonal Antibody Therapeutics Market?

Monoclonal antibody therapeutics refers to laboratory-produced molecules engineered to serve as substitute antibodies that can specifically target and bind to antigens, such as those found on cancer cells, pathogens, or immune system components. These therapies are designed to recognize and neutralize disease-causing agents or deliver drugs directly to targeted cells, making them a powerful tool in treating various diseases, including cancers, autoimmune disorders, and infectious diseases. The main types of products in monoclonal antibody therapeutics are naked, fusion protein, antibody fragment, conjugate, and multi-specific. Naked monoclonal antibodies are laboratory-made proteins that are not attached to any other molecule, such as a drug or radioactive substance. These products are used across multiple therapy areas, such as autoimmune and inflammatory disorders, oncology, hematology, ophthalmology, and others, for applications including cancer, autoimmune diseases, infection, hematological diseases, and others. They serve a broad range of end users, including hospitals, private clinics, and research institutes.

What Is The Monoclonal Antibody Therapeutics Market Growth Forecast?

The monoclonal antibody therapeutics market size is expected to see rapid growth in the next few years. It will grow to $396.1 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to advances in bispecific and multi-specific antibodies, increased biologics and fusion protein production, rising autoimmune and infectious disease prevalence, expansion of hospital and private clinic adoption, integration of ai and automation in drug discovery. Major trends in the forecast period include rising investment in monoclonal antibody research and development, expansion of oncology and autoimmune therapeutics, increasing adoption of antibody-drug conjugates, growth in personalized and targeted therapies, enhancement of clinical trial infrastructure and biomanufacturing capabilities.

Global Monoclonal Antibody Therapeutics Market Segmentation

1) By Product Type: Naked, Fusion Protein, Antibody Fragment, Conjugate, Multi-Specific 2) By Therapy Area: Autoimmune And Inflammatory Disorders, Oncology, Hematology, Ophthalmology, Other Therapy Areas 3) By Application: Cancer, Autoimmune Diseases, Infection, Hematological Diseases, Other Applications 4) By End User: Hospitals, Private Clinics, Research Institute Subsegments: 1) By Naked: Fully Human Antibodies, Humanized Antibodies, Chimeric Antibodies 2) By Fusion Protein: Receptor Fusion Proteins, Ligand Fusion Proteins 3) By Antibody Fragment: Single-Chain Variable Fragment, Fab Fragments, Diabodies 4) By Conjugate: Antibody-Drug Conjugates, Radioimmunoconjugates, Immunotoxins 5) By Multi-Specific: Bispecific Antibodies, Trispecific Antibodies, T-Cell Engagers

What Is The Driver Of The Monoclonal Antibody Therapeutics Market?

The rising prevalence of autoimmune diseases is expected to propel the growth of the monoclonal antibody therapeutics market going forward. Autoimmune diseases refer to conditions in which the body’s immune system mistakenly attacks its own healthy tissues and organs, perceiving them as foreign threats, leading to chronic inflammation and tissue damage. The prevalence of autoimmune diseases is rising due to environmental changes, as increased exposure to pollutants and altered microbial environments are believed to trigger abnormal immune responses in susceptible individuals. Monoclonal antibody therapeutics are useful for autoimmune diseases as they precisely target and block specific immune pathways responsible for inflammation and tissue damage, helping to reduce symptoms and slow disease progression. For instance, in November 2023, according to the Multiple Sclerosis International Federation (MSIF), a UK-based international nonprofit organization, an estimated 2.9 million people worldwide were living with multiple sclerosis, a type of autoimmune and immune-mediated disease, in 2023. Therefore, the rising prevalence of autoimmune diseases is driving the growth of the monoclonal antibody therapeutics industry.

Key Players In The Global Monoclonal Antibody Therapeutics Market

Major companies operating in the monoclonal antibody therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Genmab A/S, ADC Therapeutics, Y‑mAbs Therapeutics.

Global Monoclonal Antibody Therapeutics Market Trends and Insights

Major companies operating in the monoclonal antibody therapeutics market are focusing on introducing innovative solutions, such as bispecific monoclonal antibodies, to enhance treatment efficacy by simultaneously targeting two different antigens or epitopes. Bispecific monoclonal antibodies refer to a specialized class of engineered antibodies that can simultaneously bind to two different antigens or two distinct epitopes on the same antigen. For instance, in March 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched Vabysmo (faricimab-svoa), a bispecific monoclonal antibody for eye diseases, designed to treat neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). It targets both VEGF-A and Angiopoietin-2 (Ang-2), offering improved vascular stability and reducing retinal fluid leakage. Its dual-target mechanism allows for extended dosing intervals of up to four months, significantly lowering treatment burden for patients.

What Are Latest Mergers And Acquisitions In The Monoclonal Antibody Therapeutics Market?

In February 2024, AbbVie Inc., a US-based biopharmaceutical company, partnered with OSE Immunotherapeutics SA to develop a novel monoclonal antibody aimed at treating chronic and severe inflammation. This collaboration aims to develop and commercialize a novel monoclonal antibody, OSE-230, that activates ChemR23 to effectively resolve chronic inflammation and improve treatment outcomes for patients with severe inflammatory diseases. OSE Immunotherapeutics SA is a France-based company focused on developing innovative immunotherapies, including monoclonal antibody therapeutics, for cancer and autoimmune diseases.

Regional Insights

North America was the largest region in the monoclonal antibody therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Monoclonal Antibody Therapeutics Market?

The monoclonal antibody therapeutics market consists of sales of murine monoclonal antibodies, humanized monoclonal antibodies, antibody-drug conjugates, anti-infective monoclonal antibodies, and immune effector cell engagers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Monoclonal Antibody Therapeutics Market Report 2026?

The monoclonal antibody therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the monoclonal antibody therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.